

SUPPLEMENTARY MATERIALS

Piccolo R, Gu YL, Iversen AZ, Dominguez-Rodriguez A, de Smet B JGL, Mahmoud KD, Eitel I, Abreu-Gonzalez P, Bertrand OF, Thiele H, and Piscione F

Clinical Impact of Intracoronary Abciximab in Patients Undergoing Primary Percutaneous Coronary Intervention: an Individual Patient-Data Pooled Analysis of Randomized Studies

eMethods – Search Strategy.

eTable 1A – Clinical characteristics of the study population in the CICERO Trial.

eTable 1B – Clinical characteristics of the study population in the study of Dominguez-Rodriguez et al.

eTable 1C – Clinical characteristics of the study population in the EASY-MI Trial.

eTable 1D – Clinical characteristics of the study population in the study of Iversen et al.

eTable 1E – Clinical characteristics of the study population in the study of Thiele et al.

eTable 2 – Univariate and Multivariate Predictors of Death and Reinfarction.

eMethods – Search Strategy.

Search strategy for PubMed:

((("random allocation"[MeSH Terms] OR ("random"[All Fields] AND "allocation"[All Fields]) OR "random allocation"[All Fields] OR "randomized"[All Fields]) AND ("clinical trials as topic"[MeSH Terms] OR ("clinical"[All Fields] AND "trials"[All Fields] AND "topic"[All Fields]) OR "clinical trials as topic"[All Fields] OR "trial"[All Fields])) AND ("myocardial infarction"[MeSH Terms] OR ("myocardial"[All Fields] AND "infarction"[All Fields]) OR "myocardial infarction"[All Fields]) OR (ST-segment[All Fields] AND elevation[All Fields]) AND (percutaneous[All Fields] AND ("heart"[MeSH Terms] OR "heart"[All Fields] OR "coronary"[All Fields]) AND ("Intervention (Amstelveen)"[Journal] OR "intervention"[All Fields])) OR (primary[All Fields] AND percutaneous[All Fields] AND ("heart"[MeSH Terms] OR "heart"[All Fields] OR "coronary"[All Fields]) AND ("Intervention (Amstelveen)"[Journal] OR "intervention"[All Fields])) OR (primary[All Fields] AND ("angioplasty"[MeSH Terms] OR "angioplasty"[All Fields])) AND (("platelet glycoprotein gpiib-iii_a complex"[MeSH Terms] OR ("platelet"[All Fields] AND "glycoprotein"[All Fields] AND "gpiib-iii_a"[All Fields] AND "complex"[All Fields]) OR "platelet glycoprotein gpiib-iii_a complex"[All Fields] OR ("glycoprotein"[All Fields] AND "iib iii_a"[All Fields]) OR "glycoprotein iib iii_a"[All Fields]) AND ("antagonists and inhibitors"[Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields])) AND ("1"[PDAT] : "2010/11/15"[PDAT]) AND ("1"[PDAT] : "2010/11/15"[PDAT])

Search strategy for EMBASE:

randomized AND trial AND myocardial AND ('infarction'/exp OR infarction) OR 'st segment'/exp OR 'st segment' AND elevation AND percutaneous AND coronary AND intervention OR primary AND percutaneous AND coronary AND intervention OR primary AND ('angioplasty'/exp OR angioplasty) AND ('abciximab'/exp OR abciximab) AND intracoronary AND ('glycoprotein'/exp OR glycoprotein) AND inhibitors.

eTable 1A - Clinical characteristics of the study population in the CICERO Trial.

	Intracoronary abciximab (n=271)	Intravenous abciximab (n=263)	P
Age, yrs	64±13	64±13	0.94
Male, n (%)	208 (76.8)	187 (71.1)	0.14
Hypertension, n (%)	119 (43.9)	129 (49)	0.23
Dyslipidemia, n (%)	80 (29.5)	74 (28.1)	0.72
Current smoker, n (%)	116 (42.8)	127 (48.3)	0.20
Diabetes, n (%)	36 (13.3)	29 (11)	0.42
Family CAD history, n (%)	125 (46.1)	124 (47.1)	0.81
Previous MI, n (%)	32 (11.8)	23 (8.7)	0.24
Previous revascularization, n (%)	25 (9.2)	25 (9.5)	0.91
Time to reperfusion, min*	225±154	231±157	0.64
Thrombectomy, n (%)	266 (98.2)	255 (97)	0.37
Clopidogrel 600 mg loading dose, n (%)	271 (100)	261 (99.2)	0.24
Drug-eluting stent, n (%)	48 (17.7)	46 (17.5)	0.94
Anterior myocardial infarction, n (%)	124 (45.8)	129 (49)	0.45
Diseased vessel, n (%)			0.29
1	123 (45.4)	101 (38.7)	
2	78 (28.8)	84 (32.2)	
3	70 (25.8)	76 (29.1)	
Infarct-related vessel, n (%)			0.72
No infarct-related artery	0	0	
Left anterior descending	121 (44.6)	124 (47.1)	
Left circumflex	33 (12.2)	34 (12.9)	
Right coronary	114 (42.1)	100 (38)	
Left main	3 (1.1)	5 (1.9)	
Saphenous-vein graft	0	0	
TIMI flow grade pre-PCI, n (%)			0.05
0	125 (46.1)	145 (55.1)	
1	25 (9.2)	31 (11.8)	
2	64 (23.6)	49 (18.6)	
3	57 (21)	38 (14.4)	
TIMI flow grade post-PCI, n (%)			0.39
0	1 (0.4)	0	
1	2 (0.7)	1 (0.4)	
2	26 (9.6)	35 (13.4)	
3	241 (89.3)	226 (86.3)	

eTable 1B - Clinical characteristics of the study population in the study of Dominguez-Rodriguez et al.

	Intracoronary abciximab (n=50)	Intravenous abciximab (n=50)	P
Age, yrs	66±17	69±15	0.51
Male, n (%)	18 (72)	20 (80)	0.51
Hypertension, n (%)	14 (56)	13 (52)	0.78
Dyslipidemia, n (%)	17 (68)	22 (88)	0.09
Current smoker, n (%)	22 (88)	20 (80)	0.70
Diabetes, n (%)	13 (52)	15 (60)	0.57
Family CAD history, n (%)	2 (8)	3 (12)	1.00
Previous MI, n (%)	4 (16)	4 (16)	1.00
Previous revascularization, n (%)	0	0	----
Time to reperfusion, min*	142±42	151±26	0.39
Thrombectomy, n (%)	25 (100)	25 (100)	----
Clopidogrel 600 mg loading dose, n (%)	0	0	----
Drug-eluting stent, n (%)	25 (100)	25 (100)	----
Anterior myocardial infarction, n (%)	14 (56)	16 (64)	0.56
Diseased vessel, n (%)			0.82
1	13 (52)	15 (60)	
2	9 (36)	8 (32)	
3	3 (12)	2 (8)	
Infarct-related vessel, n (%)			0.77
No infarct-related artery	0	0	
Left anterior descending	14 (56)	16 (64)	
Left circumflex	6 (24)	4 (16)	
Right coronary	5 (20)	5 (20)	
Left main	0	0	
Saphenous-vein graft	0	0	
TIMI flow grade pre-PCI, n (%)			1.00
0	21 (84)	20 (80)	
1	4 (16)	5 (20)	
2	0	0	
3	0	0	
TIMI flow grade post-PCI, n (%)			0.13
0	0	0	
1	0	3 (12)	
2	3 (12)	5 (20)	
3	22 (88)	17 (68)	

eTable 1C - Clinical characteristics of the study population in the EASY-MI Trial.

	Intracoronary abciximab (n=53)	Intravenous abciximab (n=52)	P
Age, yrs	59±9	59±9	0.96
Male, n (%)	41 (77.4)	43 (82.7)	0.49
Hypertension, n (%)	23 (43.3)	23 (44.2)	0.93
Dyslipidemia, n (%)	24 (45.3)	26 (50)	0.63
Current smoker, n (%)	37 (69.8)	40 (76.9)	0.41
Diabetes, n (%)	4 (7.5)	5 (9.6)	0.74
Family CAD history, n (%)	35 (66)	37 (71.2)	0.52
Previous MI, n (%)	6 (11.3)	9 (17.3)	0.38
Previous revascularization, n (%)	3 (5.7)	7 (13.5)	0.20
Time to reperfusion, min*	177±73	177±77	0.97
Thrombectomy, n (%)	21 (39.6)	23 (44.2)	0.63
Clopidogrel 600 mg loading dose, n (%)	47 (88.7)	37 (71.2)	0.02
Drug-eluting stent, n (%)	50 (94.3)	50 (96.2)	1.00
Anterior myocardial infarction, n (%)	17 (32.1)	16 (30.8)	0.88
Diseased vessel, n (%)			0.52
1	30 (56.6)	35 (67.3)	
2	17 (32.1)	13 (25)	
3	6 (11.3)	4 (7.7)	
Infarct-related vessel, n (%)			0.48
No infarct-related artery	0	0	
Left anterior descending	22 (41.5)	21 (40.4)	
Left circumflex	5 (9.4)	2 (3.8)	
Right coronary	26 (49.1)	29 (55.8)	
Left main	0	0	
Saphenous-vein graft	0	0	
TIMI flow grade pre-PCI, n (%)			0.68
0	30 (56.6)	31 (59.6)	
1	6 (11.3)	8 (15.4)	
2	14 (26.4)	9 (17.3)	
3	3 (5.7)	4 (7.7)	
TIMI flow grade post-PCI, n (%)			0.46
0	1 (1.9)	0	
1	0	0	
2	3 (5.7)	5 (9.6)	
3	49 (92.5)	47 (90.4)	

eTable 1D - Clinical characteristics of the study population in the study of Iversen et al.

	Intracoronary abciximab (n=185)	Intravenous abciximab (n=170)	P
Age, yrs	61±11	62±11	0.76
Male, n (%)	151 (81.6)	135 (79.4)	0.60
Hypertension, n (%)	73 (39.5)	68 (40)	0.92
Dyslipidemia, n (%)	80 (43.2)	67 (39.4)	0.46
Current smoker, n (%)	92 (49.7)	89 (52.4)	0.62
Diabetes, n (%)	26 (14.1)	18 (10.6)	0.32
Family CAD history, n (%)	71 (38.4)	54 (31.8)	0.19
Previous MI, n (%)	35 (18.9)	30 (17.6)	0.76
Previous revascularization, n (%)	35 (18.9)	30 (17.6)	0.76
Time to reperfusion, min*	----	----	
Thrombectomy, n (%)	0	0	----
Clopidogrel 600 mg loading dose, n (%)	178 (96.2)	163 (95.9)	0.87
Drug-eluting stent, n (%)	147 (79.5)	133 (78.2)	0.78
Anterior myocardial infarction, n (%)	79 (42.7)	78 (45.9)	0.55
Diseased vessel, n (%)			0.49
1	119 (64.3)	118 (69.4)	
2	43 (23.2)	31 (18.2)	
3	23 (12.4)	21 (12.4)	
Infarct-related vessel, n (%)			0.53
No infarct-related artery	2 (1.1)	0	
Left anterior descending	88 (47.6)	86 (50.6)	
Left circumflex	16 (8.6)	16 (9.4)	
Right coronary	79 (42.7)	68 (40)	
Left main	0	0	
Saphenous-vein graft	0	0	
TIMI flow grade pre-PCI, n (%)			0.12
0	134 (72.4)	132 (77.6)	
1	19 (10.3)	21 (12.4)	
2	16 (8.6)	5 (2.9)	
3	16 (8.6)	12 (7.1)	
TIMI flow grade post-PCI, n (%)			0.33
0	2 (1.1)	4 (2.4)	
1	8 (4.3)	12 (7.1)	
2	26 (14.1)	39 (17.6)	
3	149 (80.5)	124 (72.9)	

eTable 1E - Clinical characteristics of the study population in the study of Thiele et al.

	Intracoronary abciximab (n=77)	Intravenous abciximab (n=77)	P
Age, yrs	62±11	64±11	0.28
Male, n (%)	63 (81.8)	59 (76.6)	0.43
Hypertension, n (%)	54 (70.1)	57 (74)	0.59
Dyslipidemia, n (%)	27 (35.1)	31 (40.3)	0.51
Current smoker, n (%)	38 (49.4)	39 (50.6)	0.87
Diabetes, n (%)	24 (31.2)	22 (28.6)	0.72
Family CAD history, n (%)	20 (26)	21 (27.3)	0.85
Previous MI, n (%)	8 (10.4)	7 (9.1)	0.79
Previous revascularization, n (%)	7 (9.1)	7 (9.1)	1.00
Time to reperfusion, min*	297±175	274±175	0.43
Thrombectomy, n (%)	0	0	----
Clopidogrel 600 mg loading dose, n (%)	77 (100)	77 (100)	1.00
Drug-eluting stent, n (%)	58 (75.3)	51 (66.2)	0.21
Anterior myocardial infarction, n (%)	44 (57.1)	40 (51.9)	0.52
Diseased vessel, n (%)			0.89
1	40 (51.9)	37 (48.1)	
2	24 (31.2)	26 (33.8)	
3	13 (16.9)	14 (18.2)	
Infarct-related vessel, n (%)			0.42
No infarct-related artery	0	0	
Left anterior descending	42 (54.5)	35 (45.5)	
Left circumflex	8 (10.4)	10 (13)	
Right coronary	27 (35.1)	29 (37.7)	
Left main	0	1 (1.3)	
Saphenous-vein graft	0	2 (2.6)	
TIMI flow grade pre-PCI, n (%)			0.51
0	44 (57.1)	52 (67.5)	
1	9 (11.7)	5 (6.5)	
2	6 (7.8)	4 (5.2)	
3	18 (23.4)	16 (20.8)	
TIMI flow grade post-PCI, n (%)			0.90
0	1 (1.3)	2 (2.6)	
1	1 (1.3)	1 (1.3)	
2	10 (13)	8 (10.4)	
3	65 (84.4)	66 (85.7)	

eTable 2 - Univariate and Multivariate Predictors of Death and Reinfarction

Parameter	Univariate Predictors				Multivariate Predictors			
	β	SE	Hazard Ratio (95% CI)	p-value	B	SE	Hazard Ratio (95% CI)	p-value
Age	0.055	0.012	1.06 (1.03-1.08)	<0.001	0.046	0.13	1.05 (1.02-1.07)	<0.001
Three-vessel disease	1.222	0.285	3.39 (1.94-5.93)	<0.001	1.016	0.291	2.76 (1.56-4.88)	<0.001
Previous MI	0.867	0.322	2.38 (1.26-4.48)	0.007	0.698	0.325	2.01 (1.06-3.80)	0.03
Hypertension	0.501	0.289	1.65 (0.94-2.91)	0.08				
Anterior MI	0.467	0.287	1.59 (0.91-2.79)	0.10				
Intracoronary abciximab	-0.62	0.295	0.54 (0.30-0.95)	0.03	-0.576	0.295	0.56 (0.31-1.00)	0.05

All p values are from Cox proportional hazard model. Variables tested in models: Age, Sex, Hypertension, Dyslipidemia, Current smoker, Diabetes, Family history for coronary artery disease, Previous myocardial infarction, Previous revascularization, Thrombectomy, Clopidogrel 600 mg loading dose, drug-eluting stent implantation, anterior myocardial infarction, diseased vessel, infarct-related vessel, TIMI flow grade pre-procedure, TIMI flow grade post-procedure.

MI= myocardial infarction.